These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 23774998)

  • 1. Building a European consensus on minimum quality standards for drug treatment, rehabilitation and harm reduction.
    Schaub MP; Uchtenhagen A;
    Eur Addict Res; 2013; 19(6):314-24. PubMed ID: 23774998
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Operationalization of food consumption surveys in Europe: recommendations from the European Food Consumption Survey Methods (EFCOSUM) Project.
    De Henauw S; Brants HA; Becker W; Kaic-Rak A; Ruprich J; Sekula W; Mensink GB; Koenig JS;
    Eur J Clin Nutr; 2002 May; 56 Suppl 2():S75-88. PubMed ID: 12082520
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Implementation of quality standards in drug demand reduction: Insights from FENIQS-EU project and ways forward.
    Serdar K; Feric M; Belosevic M; Jerkovic D; González-Roz A; Vanderplasschen W
    Adicciones; 2023 Nov; 0(0):1891. PubMed ID: 39033521
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acceptability and availability of harm-reduction interventions for drug abuse in American substance abuse treatment agencies.
    Rosenberg H; Phillips KT
    Psychol Addict Behav; 2003 Sep; 17(3):203-10. PubMed ID: 14498814
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Mangement of drug problems in Hungary].
    Buda B
    Lege Artis Med; 2009 Sep; 19(8-9):537-41. PubMed ID: 20608432
    [No Abstract]   [Full Text] [Related]  

  • 6. Practitioners' attitudes concerning evidence-based guidelines in Belgian substance abuse treatment.
    Autrique M; Vanderplasschen W; Broekaert E; Sabbe B
    Eur Addict Res; 2009; 15(1):47-55. PubMed ID: 19052462
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Strategies for implementation of harm reduction in treatment settings.
    Denning P
    J Psychoactive Drugs; 2001; 33(1):23-6. PubMed ID: 11332997
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heroin-assisted treatment in Switzerland: a case study in policy change.
    Uchtenhagen A
    Addiction; 2010 Jan; 105(1):29-37. PubMed ID: 19922519
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Dual Diagnosis Capability of Residential Addiction Treatment centres: priorities and confidence to improve capability following a review process.
    Matthews H; Kelly PJ; Deane FP
    Drug Alcohol Rev; 2011 Mar; 30(2):195-9. PubMed ID: 21355921
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A cross-sectional national survey assessing self-reported drug intake behavior, contact with the primary sector and drug treatment among service users of Danish drug consumption rooms.
    Toth EC; Tegner J; Lauridsen S; Kappel N
    Harm Reduct J; 2016 Oct; 13(1):27. PubMed ID: 27717366
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The ethical, legal and social context of harm reduction.
    Pauly B; Goldstone I; McCall J; Gold F; Payne S
    Can Nurse; 2007 Oct; 103(8):19-23. PubMed ID: 17990401
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent trends in drug treatment in Europe.
    Kinnunen A; Nilson M
    Eur Addict Res; 1999 Sep; 5(3):145-52. PubMed ID: 10460979
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The NCI All Ireland Cancer Conference.
    Johnston PG; Daly PA; Liu E
    Oncologist; 1999; 4(4):275-277. PubMed ID: 10545862
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assess, compare and enhance the status of Persons with Multiple Sclerosis (MS) in Europe: a European Register for MS.
    Pugliatti M; Eskic D; Mikolcić T; Pitschnau-Michel D; Myhr KM; Sastre-Garriga J; Otero S; Wieczynska L; Torje C; Holloway E; Rienhoff O; Friede T; Buckow K; Ellenberger D; Hillert J; Glaser A; Flachenecker P; Fuge J; Schyns-Liharska T; Kasilingam E; Moretti A; Thalheim C;
    Acta Neurol Scand Suppl; 2012; (195):24-30. PubMed ID: 23278653
    [TBL] [Abstract][Full Text] [Related]  

  • 16. What is the role of harm reduction when drug users say they want abstinence?
    Neale J; Nettleton S; Pickering L
    Int J Drug Policy; 2011 May; 22(3):189-93. PubMed ID: 21055914
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Procedures and methods of benefit assessments for medicines in Germany].
    Bekkering GE; Kleijnen J
    Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Towards the integration of treatment systems for substance abusers: report on the second International Symposium on Substance Abuse Treatment and Special Target Groups.
    Broekaert E; Vanderplasschen W
    J Psychoactive Drugs; 2003; 35(2):237-45. PubMed ID: 12924746
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The issue of harm reduction in Polish legislation concerning drug addiction. A comparative study].
    Sobeyko J
    Ann Acad Med Stetin; 2008; 54(2):119-31. PubMed ID: 19374242
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Harm reduction--from a conceptual framework to practical experience: the example of Germany.
    Michels II; Stöver H
    Subst Use Misuse; 2012; 47(8-9):910-22. PubMed ID: 22676562
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.